Korean ginseng berry fermented by mycotoxin non-producing Aspergillus niger and Aspergillus oryzae: Ginsenoside analyses and anti-proliferative activities

Biological and Pharmaceutical Bulletin

Volumn 39, Issue 9, 2016, Pages 1461-1467

  Li, Zhipeng ^a   Ahn, Hyung Jin ^a   Kim, Nam Yeon ^a   Lee, Yu Na ^a   Ji, Geun Eog ^a,b  

^a Seoul National University   (South Korea)

^b Bifido Co   (South Korea)

Author keywords

Anti proliferation; Ginsenoside; Korean ginseng berry (KGB); Mold; Mycotoxin; Transformation

Indexed keywords

GINSENG EXTRACT; GINSENOSIDE; GINSENOSIDE K; GINSENOSIDE RB 1; GINSENOSIDE RB 2; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; GINSENOSIDE RH1; MYCOTOXIN; PROTOPANAXADIOL; UNCLASSIFIED DRUG; PLANT EXTRACT;

ADENOCARCINOMA CELL LINE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASPERGILLUS NIGER; ASPERGILLUS ORYZAE; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DECOMPOSITION; DRUG STRUCTURE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; FERMENTATION; FRUIT; HEP-G2 CELL LINE; HT-29 CELL LINE; METABOLISM; PANAX;

ASPERGILLUS NIGER; ASPERGILLUS ORYZAE; CELL PROLIFERATION; FERMENTATION; FRUIT; GINSENOSIDES; HEP G2 CELLS; HT29 CELLS; HUMANS; MYCOTOXINS; PANAX; PLANT EXTRACTS;

EID: 84984878652     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b16-00239     Document Type: Article

References (47)

1. Han GC, Ko SK, Sung JH, Chung SH. Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. J. Agric. Food Chem., 55, 10641-10648 (2007).
2. Xie J-T, Mehendale SR, Li X, Quigg R, Wang X, Wang C-Z, Wu JA, Aung HH, Rue PA, Bell GI, Yuan C-S. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1740, 319-325 (2005).
3. Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I, Shinomiya N. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn. J. Cancer Res., 89, 733-740 (1998).
4. Wakabayashi C, Hasegawa H, Murata J, Saiki I. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol. Res., 9, 411-417 (1997).
5. Ko SK, Bae HM, Cho OS, Im BO, Chung SH, Lee BY. Analysis of ginsenoside composition of ginseng berry and seed. Food Sci. Biotechnol., 17, 1379-1382 (2008).
6. Wang C-Z, Zhang B, Song W-X, Wang A, Ni M, Luo X, Aung HH, Xie J-T, Tong R, He T-C, Yuan CS. Steamed American ginseng berry: ginsenoside analyses and anticancer activities. J. Agric. Food Chem., 54, 9936-9942 (2006).
7. Kim D. Intestinal microflora activate the pharmacological effects of herbal medicines. Nat. Prod. Sci., 8, 35-43 (2002).
8. Kobashi K, Akao T. Relation of intestinal bacteria to pharmacological effects of glycosides. Biosci. Microflora, 16, 1-7 (1997).
9. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab. Dispos., 31, 1065-1071 (2003).
10. Yim J-S, Kim Y-S, Moon S-K, Cho K-H, Bae H-S, Kim J-J, Park E-K, Kim D-H. Metabolic activities of ginsenoside Rb1, baicalin, glycyrrhizin and geniposide to their bioactive compounds by human intestinal microflora. Biol. Pharm. Bull., 27, 1580-1583 (2004).
11. Choo M-K, Park E-K, Han MJ, Kim D-H. Antiallergic activity of ginseng and its ginsenosides. Planta Med., 69, 518-522 (2003).
12. Han BH, Park M, Han Y, Woo L, Sankawa U, Yahara S, Tanaka O. Degradation of ginseng saponins under mild acidic conditions. Planta Med., 44, 146-149 (1982).
13. Chen YJ, Nose M, Ogihara Y. Alkaline cleavage of ginsenosides. Chem. Pharm. Bull., 35, 1653-1655 (1987).
14. Ko S-R, Choi K-J, Uchida K, Suzuki Y. Enzymatic preparation of ginsenosides Rg2, Rh1, and F1 from protopanaxatriol-type ginseng saponin mixture. Planta Med., 69, 285-286 (2003).
15. Chi H, Ji G-E. Transformation of ginsenosides Rb1 and Re from Panax ginseng by food microorganisms. Biotechnol. Lett., 27, 765-771 (2005).
16. Chi H, Kim D-H, Ji G-E. Transformation of ginsenosides Rb2 and Rc from Panax ginseng by food microorganisms. Biol. Pharm. Bull., 28, 2102-2105 (2005).
17. Kim NY, Lee I, Ji GE. Reliable and simple detection of ochratoxin and fumonisin production in black Aspergillus. J. Food Prot., 77, 653-658 (2014).
18. Kim NY, Lee JH, Lee I, Ji GE. An evaluation of aflatoxin and cyclopiazonic acid production in Aspergillus oryzae. J. Food Prot., 77, 1010-1016 (2014).
19. Blumenthal CZ. Production of toxic metabolites in Aspergillus niger, Aspergillus oryzae, and Trichoderma reesei: justification of mycotoxin testing in food grade enzyme preparations derived from the three fungi. Regul. Toxicol. Pharmacol., 39, 214-228 (2004).
20. Sanchez JF, Somoza AD, Keller NP, Wang CC. Advances in Aspergillus secondary metabolite research in the post-genomic era. Nat. Prod. Rep., 29, 351-371 (2012).
21. Li W, Zhang M, Gu J, Meng Z-, Zhao L-C, Zheng Y-, Chen L, Yang G-L. Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound K on Type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis. Fitoterapia, 83, 192-198 (2012).
22. Chae S, Kang KA, Chang WY, Kim MJ, Lee SJ, Lee YS, Kim HS, Kim DH, Hyun JW. Effect of compound K, a metabolite of ginseng saponin, combined with γ-ray radiation in human lung cancer cells in vitro and in vivo. J. Agric. Food Chem., 57, 5777-5782 (2009).
23. Kim DY, Park MW, Yuan HD, Lee HJ, Kim SH, Chung SH. Compound K induces apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. J. Agric. Food Chem., 57, 10573-10578 (2009).
24. Kim DY, Yuan HD, Chung IK, Chung SH. Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. J. Agric. Food Chem., 57, 1532-1537 (2009).
25. Song G, Guo S, Wang W, Hu C, Mao Y, Zhang B, Zhang H, Hu T. Intestinal metabolite compound K of ginseng saponin potently attenuates metastatic growth of hepatocellular carcinoma by augmenting apoptosis via a Bid-mediated mitochondrial pathway. J. Agric. Food Chem., 58, 12753-12760 (2010).
26. Yoon J-H, Choi Y-J, Lee S-G. Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells. Eur. J. Pharmacol., 679, 24-33 (2012).
27. Zheng H, Jeong Y, Song J, Ji GE. Oral administration of ginsenoside Rh1 inhibits the development of atopic dermatitis-like skin lesions induced by oxazolone in hairless mice. Int. Immunopharmacol., 11, 511-518 (2011).
28. Gu W, Kim K-A, Kim D-H. Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation. Biol. Pharm. Bull., 36, 102-107 (2013).
29. Wang Y-Z, Chen J, Chu S-F, Wang Y-S, Wang X-Y, Chen N-H, Zhang J-T. Improvement of memory in mice and increase of hippocampal excitability in rats by ginsenoside Rg1's metabolites ginsenoside Rh1 and protopanaxatriol. J. Pharmacol. Sci., 109, 504-510 (2009).
30. Baek N-I, Kim DS, Lee YH, Park JD, Lee CB, Kim SI. Cytotoxicities of ginseng saponins and their degradation products against some cancer cell lines. Arch. Pharm. Res., 18, 164-168 (1995).
31. Chang YS, Seo E-K, Gyllenhaal C, Block KI. Panax ginseng: a role in cancer therapy? Integr. Cancer Ther., 2, 13-33 (2003).
32. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern. Med. Rev., 9, 259-274 (2004).
33. Shin HR, Kim JY, Yun TK, Morgan G, Vainio H. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control, 11, 565-576 (2000).
34. Yun T-K. Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat. Res., 523-524, 63-74 (2003).
35. Yun T-K, Choi S-Y. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol. Biomarkers Prev., 4, 401-408 (1995).
36. Yun T-K, Choi SY. A case-control study of ginseng intake and cancer. Int. J. Epidemiol., 19, 871-876 (1990).
37. Yun T-K, Choi S-Y. Non-organ specific cancer prevention of ginseng: a prospective study in Korea. Int. J. Epidemiol., 27, 359-364 (1998).
38. Suh SO, Kroh M, Kim NR, Joh YG, Cho MY. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. Am. J. Chin. Med., 30, 483-494 (2002).
39. Jung SH, Woo MS, Kim SY, Kim WK, Hyun JW, Kim EJ, Kim DH, Kim HS. Ginseng saponin metabolite suppresses phorbol ester-induced matrix metalloproteinase-9 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathways in human astroglioma cells. Int. J. Cancer, 118, 490-497 (2006).
40. Park M-T, Cha H-J, Jeong J-W, Kim S-I, Chung H-Y, Kim ND, Kim OH, Kim K-W. Glucocorticoid receptor-induced down-regulation of MMP-9 by ginseng components, PD and PT contributes to inhibition of the invasive capacity of HT1080 human fibrosarcoma cells. Mol. Cells, 9, 476-483 (1999).
41. Hasegawa H, Suzuki R, Nagaoka T, Tezuka Y, Kadota S, Saiki I. Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol. Biol. Pharm. Bull., 25, 861-866 (2002).
42. Choi C-H, Kang G, Min Y-D. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med., 69, 235-240 (2003).
43. Jin J, Shahi S, Kang HK, van Veen HW, Fan T-P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun., 345, 1308-1314 (2006).
44. Akao T, Kanaoka M, Kobashi K. Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration. Measurement of compound K by enzyme immunoassay. Biol. Pharm. Bull., 21, 245-249 (1998).
45. Lee Y, Jin Y, Lim W, Ji S, Choi S, Jang S, Lee S. A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells. J. Steroid Biochem. Mol. Biol., 84, 463-468 (2003).
46. Yang CS, Ko SR, Cho BG, Shin DM, Yuk JM, Li S, Kim JM, Evans RM, Jung JS, Song DK, Jo EK. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. J. Cell. Mol. Med., 12 (5A), 1739-1753 (2008).
47. Dey L, Xie J, Wang A, Wu J, Maleckar S, Yuan C-S. Anti-hyperglycemic effects of ginseng: comparison between root and berry. Phytomedicine, 10, 600-605 (2003).